These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 9833724)

  • 1. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
    van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
    J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
    Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
    Walenga JM; Bakhos M; Messmore HL; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):105-11. PubMed ID: 1772977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia.
    Longrois D; de Maistre E; Bischoff N; Dopff C; Meistelman C; Angioï M; Lecompte T
    Can J Anaesth; 2000 Mar; 47(3):255-60. PubMed ID: 10730738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
    Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
    Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN
    J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model.
    Walenga JM; Bakhos M; Messmore HL; Fareed J; Pifarre R
    Ann Thorac Surg; 1991 Feb; 51(2):271-7. PubMed ID: 1989543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR; Walenga JM; Koza MJ; Pifarré R
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
    Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
    von Segesser LK; Mueller X; Marty B; Horisberger J; Corno A
    Perfusion; 2001 Sep; 16(5):411-6. PubMed ID: 11565896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study.
    Riess FC; Poetzsch B; Madlener K; Cramer E; Doll KN; Doll S; Lorke DE; Kormann J; Mueller-Berghaus G
    Thorac Cardiovasc Surg; 2007 Jun; 55(4):233-8. PubMed ID: 17546553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Heparin-Resistant Patients with Benefits? Maximizing Biocompatibility in Cardiopulmonary Bypass: Combining ATryn® Recombinant Antithrombin III and Carmeda® Heparin-Bonded Perfusion Circuits: A Case Series.
    Chryssos A; Stroup SJ; Pifer MM; Tawil M; Conrad CG
    J Extra Corpor Technol; 2015 Mar; 47(1):44-7. PubMed ID: 26390679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model.
    Riess FC; Pötzsch B; Behr I; Jäger K; Rössing R; Bleese N; Schaper W; Müller-Berghaus G
    Eur J Cardiothorac Surg; 1997 Apr; 11(4):739-45. PubMed ID: 9151047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
    Imura Y; Stassen JM; Collen D
    J Pharmacol Exp Ther; 1992 Jun; 261(3):895-8. PubMed ID: 1602394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat.
    Welsby IJ; Jones WL; Arepally G; De Lange F; Yoshitani K; Phillips-Bute B; Grocott HP; Becker R; Mackensen GB
    Anesthesiology; 2007 Feb; 106(2):295-301. PubMed ID: 17264724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous use of argatroban and heparin during cardiopulmonary bypass.
    Okamura T; Shin'oka T; Ishibashi N; Ishii H; Kurosawa H
    Asian Cardiovasc Thorac Ann; 2010 Feb; 18(1):22-6. PubMed ID: 20124292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.